SEATTLE--(BUSINESS WIRE)--March 5, 2012--Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences:
- Cowen and Company 32nd Annual Health Care Conference in Boston, MA, on March 7, 2012, at 8:00 a.m. ET
- 24th Annual ROTH Conference in Dana Point, CA, on March 12, 2012, at 2:30 p.m. PT
- Barclays Capital Global Healthcare Conference in Miami, FL, on March 14, 2012, at 8:00 a.m. ET
The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.
About Dendreon
Dendreon Corporation is a biotechnology
company whose mission is to target cancer and transform lives through
the discovery, development, commercialization and manufacturing of novel
therapeutics. The Company applies its expertise in antigen
identification, engineering and cell processing to produce active
cellular immunotherapy (ACI) product candidates designed to stimulate an
immune response in a variety of tumor types. Dendreon’s first product,
PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010.
Dendreon is exploring the application of additional ACI product
candidates and small molecules for the potential treatment of a variety
of cancers. The Company is headquartered in Seattle, Washington, and is
traded on the NASDAQ Global Market under the symbol DNDN. For more
information about the Company and its programs, visit http://www.dendreon.com.